Outbreaks of influenza A in nursing homes in Sheffield during the 1997-1998 season: Implications for diagnosis and control

Journal of Public Health Medicine

Volumn 22, Issue 1, 2000, Pages 116-120

  Read, C A ^a   Mohsen, A ^b   Nguyen Van Tam, J S ^c   McKendrick, M ^b   Kudesia, G ^d  

^a Rotherham Health Authority   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Elderly; Influenza outbreak; Mortality; Nursing homes

Indexed keywords

INFLUENZA VACCINE; SIALIDASE INHIBITOR; ZANAMIVIR;

AGED; ARTICLE; HUMAN; INFLUENZA VIRUS A; MAJOR CLINICAL STUDY; MORTALITY; NURSING HOME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEROLOGY; UNITED KINGDOM; VACCINATION;

AGED; DISEASE OUTBREAKS; ENGLAND; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; NURSING HOMES; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; SPECIES SPECIFICITY; STATE MEDICINE;

EID: 0034061653     PISSN: 09574832     EISSN: None     Source Type: Journal    
DOI: 10.1093/pubmed/22.1.116     Document Type: Article

References (25)

1. Nguyen-Van-Tam JS, Nicholson KG. Influenza deaths in Leicestershire during the 1989-90 epidemic: implications for prevention. Epidemiol Infect 1992; 108: 537-545.
2. Warren S, Nguyen-Van-Tam JS, Pearson JCG, Madeley RJ. Practices and policies for influenza immunisation in old peoples homes in Nottingham (UK) during the 1992-1993 season: potential for improvement. J Publ Hlth Med 1995; 17: 392-396.
3. Patriarca PA, Arden N, Koplan JP, Goodman RA. Prevention and control of type A influenza infections in nursing homes: benefits and costs of four approaches using vaccination and amantadine. Ann Intern Med 1987; 107: 732-740.
4. Arden NH, Patriarca PA, Kendal AP. Experiences in the use and efficacy of inactivated vaccine in nursing homes. In: Kendall AP, Patriarca PA, eds. Options for the control of influenza. New York: Liss, 1986: 155-168.
5. Arden N, Monto AS, Ohmit SE. Vaccine use and the risks of outbreaks in a sample of nursing homes during an influenza epidemic. Am J Publ Hlth 1995; 85: 399-401.
6. Dedman DJ, Zambon M, Van Buynder P, et al. Influenza surveillance in England and Wales: October 1997 to June 1998. Communicable Dis Publ Hlth 1998; 1(4): 244-251.
7. PHLS Communicable Disease Surveillance Centre. PHLS surveillance of influenza, England and Wales 1997/98. Activity Update 1998 (21 April); 24.
8. Schmid ML, Kudesia G, Wake S, Read RC. Prospective comparative study of culture specimens and methods in diagnosing influenza infection in adults. Br Med J 1998; 316: 275.
9. Ellis JS, Fleming DM, Zambon MC. Multiplex reverse transcription-PCR for surveillance of influenza A and B viruses in England and Wales in 1995 and 1996. J Clin Microbiol 1997; 35(8): 2076-2082.
10. Dedman DJ, Zambon M, Van Buynder P, et al. Influenza surveillance in England and Wales: October 1997 to June 1998. Communicable Dis Publ Hlth 1998; 1(4): 244-251.
11. PHLS Communicable Disease Surveillance Centre. PHLS surveillance of influenza, England and Wales 1997/98. Activity Update 1998 (21 April); 24.
12. PHLS Communicable Disease Surveillance Centre. PHLS surveillance of influenza, England and Wales 1997/98. Activity Update 1997 (2 December); 6.
13. PHLS Communicable Disease Surveillance Centre. PHLS surveillance of influenza, England and Wales 1997/98. Activity Update 1998 (3 February); 15.
14. WHO. Recommended composition of influenza virus vaccine for use in the 1997-98 season. Wkly Epidemiol Rec 1997; 72: 57-61.
15. Arden NH, Patriarca PA, Kendal AP. Experiences in the use and efficacy of inactivated vaccine in nursing homes. In: Kendall AP, Patriarca PA, eds. Options for the control of influenza. New York: Liss. 1986: 155-168.
16. Arden N, Bidol S, Ohmit SE, Monto AS. Effect of nursing home size and influenza vaccination rates on the risk of institutional outbreaks during an influenza A (H3N2) epidemic. In: Hannoun C, Kendal AP, Klenk HD, Ruben FL, eds. Options for the control of influenza. Proceedings of the international conference on options for the control of influenza. Amsterdam: Elsevier, 1993: 161-165.
17. Galbraith AW, Oxford JS, Schild GC, Watson J. Study of 1-adamantanamine hydrochloride used prophylactically during the Hong Kong influenza epidemic in the family environment. Bull WHO 1969; 41: 677-682.
18. Hayden FG, Belshe RB, Clover RD, et al. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med 1989; 321: 1696-1702.
19. Capparelli EV, Stevens RC, Chow MSS, Izard M, Wills RJ. Rimantadine pharmacokinetics in healthy subjects and patients with end-stage renal failure. Clin Pharmacol Ther 1988; 43: 536-541.
20. Aoki FY, Sitar DS. Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet 1988; 14: 35-51.
21. Wiselka M. Influenza: diagnosis, management and prophylaxis. Br Med J 1994; 308: 1341-1345.
22. Hayden FG, Treanor JJ, Betts RF, et al. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA 1996; 275: 295-299.
23. Hayden FG, Osterhaus ADME, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N Engl J Med 1997; 337: 874-880.
24. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in the treatment of influenza A and B virus infections. Lancet 1998; 352: 1877-1881.
25. Mendel DB, Tai CY, Escarpe PA, et al. Oral administration of the prodrug of the neuraminidase inhibitor GS4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother 1998; 42: 640-646.